Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01495819
Other study ID # 1010007514
Secondary ID 1R01DA042528-01
Status Completed
Phase Early Phase 1
First received
Last updated
Start date January 4, 2017
Est. completion date March 31, 2020

Study information

Verified date August 2021
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed study will examine the threshold for nicotine self-administration (NSA) using five different nicotine doses in young adult male and female non-dependent smokers (light and intermittent smokers or LITS). We propose a double-blind, placebo-controlled study that will enroll 195 individuals, targeting a total of 72 completers (36 male and 36 females). In each of the five experimental sessions, smokers will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.05, 0.1 and 0.2 mg/70 kg). The highest dose, 0.2 mg/70 kg, corresponds to nicotine delivered by about one or two puffs of a cigarette. At the beginning of each experimental session, smokers will sample the assigned both the nicotine dose for that experimental session, and the placebo (saline) dose, followed by the opportunity to choose between nicotine and placebo for a total of ten choices over a 150-minute period. The main outcomes will be threshold dose (the minimum dose of nicotine that is self-administered more than placebo) and the slope of dose-response for nicotine self-administration (changes in nicotine self-administration per unit change in nicotine dose). We will also collect measures of nicotine intake (cotinine), nicotine clearance (3-hydroxycotinine (3-HC) / cotinine), and self-report drug effects


Description:

Aim #1: To assess the threshold reinforcing dose and dose-effect curve for IV NSA at low doses in young adult LITS. Hypothesis #1A: The threshold reinforcing doses for IV NSA will be between 0.0125 to 0.1 mg/70 kg. Hypothesis #1B: The dose-effect curve for NSA will differ between males and females with relatively flat curve in female smokers. Aim #2: To assess the threshold and dose-effect curve for the positive and negative/aversive subjective effects of IV nicotine at low doses and its relationship to nicotine reinforcement. Hypothesis #2 A: The threshold for the positive effects will be between 0.0125 to 0.1 mg/70 kg, for the negative/aversive effect it will be ≥ 0.1 mg/70 kg. Hypothesis #2B: Nicotine reinforcement will be positively correlated with the positive and negatively correlated with the negative/aversive subjective effects of IV nicotine. Exploratory Aims: To examine the influence of nicotine clearance rate on nicotine reinforcement threshold and dose-effect curve.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date March 31, 2020
Est. primary completion date March 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion criteria: 1) Female and male smokers, aged 18 to30 years, who have been smoking for at least a year, and a life-time consumption of at least 100 cigarettes; 2) smoke more frequently than once a week and =5 cpd; 3) FTND score <3 indicating no or minimal evidence for nicotine dependence; 4) urine cotinine levels >100 ng/mL indicating smoking status and a level <1000 mg/mL consistent with nicotine intake of LITS; 5) not seeking treatment at the time of the study for nicotine dependence; 6) in good health as verified by medical history, screening examination, and screening laboratory tests; 7) for women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods. Exclusion criteria: 1) history of major medical illnesses that the physician investigator deems as contraindicated for the subject to be in the study; 2) requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) or psychiatric diagnosis and treatment for psychiatric disorders including major depression, bipolar disorder, schizophrenia in the past 6 months; and 3) current dependence to alcohol or any other recreational or prescription drugs and; 4) daily use of smokeless tobacco products or exclusive daily use of e-cigarettes (non-daily users will be included).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Saline
5cc's of saline give at least once.
Nicotine
(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).

Locations

Country Name City State
United States Department of Veterans Affairs West Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary DEQ - Pleasurable The Drug Effects Questionnaire (DEQ) ratings subscale that measures the pleasurable effects was used. I The minimum score is zero with the maximum score of a 100millimeters.
The higher the score means the more pleasurable.
Up to 10 Minutes
Primary DEQ - Aversive The DEQ is measured using millimeters. The minimum score is zero with the maximum score of a 100millimeters. rug Effects Questionnaire (DEQ) ratings subscale that measures the aversive effects was used. The higher the score means more aversive. Up to 10 Minutes
Primary DEQ - Stimulatory The Drug Effects Questionnaire (DEQ) ratings subscale that measures the stimulatory effects was used.
DEQ is measured using millimeters. The minimum score is zero with the maximum score of a 100millimeters. The higher the score means more stimulation.
Up to10 Minutes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02643914 - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings N/A
Completed NCT02153749 - Effects of Brief Training on Craving Regulation N/A
Recruiting NCT05530577 - Effects of Semaglutide on Nicotine Intake Phase 2
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A
Completed NCT03694327 - Innovative Digital Therapeutic for Smoking Cessation N/A
Completed NCT01944423 - Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine Early Phase 1
Completed NCT01704573 - Nicotinic Receptor Levels After Stopping Smoking N/A
Active, not recruiting NCT01015170 - STOP Study: Effectiveness of Zyban in a Clinical Population Phase 4
Completed NCT03281629 - Circuitry-Guided Smoking Cessation in Schizophrenia N/A
Recruiting NCT06291584 - Effects of Exercises on Functional Capacity N/A
Withdrawn NCT06259630 - Nicotine Virtual Reality Conditioned Place Preference Phase 4
Completed NCT02624284 - tDCS Effects on Resisting Smoking: Dose Ranging Study N/A
Active, not recruiting NCT02837510 - Neural Mechanisms Associated With Risk of Smoking Relapse N/A
Completed NCT02656745 - Clinical Trial of Smoking Cessation Mobile Phone Program N/A
Completed NCT01062932 - Investigation of Cycloserine as a Smoking Cessation Treatment Phase 1
Completed NCT03069482 - Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness Phase 1
Completed NCT02870218 - Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use Phase 2
Terminated NCT01756053 - Effects of ABT-089 on Smoking Abstinence Symptoms and Reward Phase 2
Completed NCT01252966 - Cognitive Training for Nicotine Dependence N/A
Active, not recruiting NCT04946825 - Quit Smoking Study for People Who Use E-Cigarettes Phase 2